Antioxidant Treatment of Type 2 Diabetes

National Institutes of Health (NIH)

Status and phase: Completed; Early Phase 1

Conditions: Type 2 Diabetes

Treatments: Drug: n-aceylcysteine; Drug: Placebo

Study type: Interventional

Funder types: NIH

Identifiers

NCT00609102

Antioxidant trmt type 2

NIH R01 38325-19

Details and patient eligibility

About

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Enrollment: 44 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Subjects with a known diagnosis of type 2 diabetes -

Exclusion Criteria: None, except known intolerance to n-acetylcysteine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

44 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

antioxidant drug

Active Comparator group

Description:

n-acetylcysteine

Treatment:

Drug: n-aceylcysteine